Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...

Novo Nordisk has sought strength in numbers in the battle for telehealth obesity drug sales in the US, enlisting the aid of ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

After going after the companies making compounded versions of their drugs, GLP-1 makers are now going into business with the online telehealth sites that were previously selling the copycats.

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).